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Purpose: ​To apply propensity score matching to Ahmed glaucoma drainage implants (AGI) to 
trabectome-mediated ab interno trabeculectomy (AIT). Recent data suggests that AIT can produce 
results similar to AGI which is traditionally reserved for more severe glaucoma.  
 
Methods:​ AGI and AIT patients with at least one year of follow-up were included. The primary outcome 
measures were intraocular pressure (IOP), glaucoma medications, and a Glaucoma Index (GI) score. GI 
reflected glaucoma severity based on visual field, the number of preoperative medications, and 
preoperative IOP. Score matching used a genetic algorithm consisting of age, gender, type of glaucoma, 
concurrent phacoemulsification, baseline number of medications, and baseline IOP. Patients without a 
close match were excluded.  
 
Results:​ Of 152 patients, 34 AIT patients were matched to 32 AGI patients. Baseline characteristics 
including ethnicity, IOP, the number of medications, glaucoma type, the degree of VF loss and GI were 
not significantly different between AIT and AGI. AIT had a preoperative IOP of 23.6±8.1 mmHg compared 
to 26.5+10.6 for AGI. At 12 months, the mean IOP was 15.0±9 mmHg for AIT versus 15.0±4 mmHg for 
AGI (p=0.8), while the number of drops was 2.3±2.2 for AIT versus 3.6±1.3 for AGI (p=0.016). Only 6 AIT 
patients (17.6%) required further surgery within the first 12 months versus 9 (28%) for AGI. Success, 
defined as IOP<21 mmHg, <20% reduction and no reoperation, was achieved in 76% of AIT versus 69% of 
AGI (p=0.48). Complications occurred in 13% of AGI and 0.8% of AIT. 
 
Conclusions: ​A propensity score matched comparison of AIT and AGI demonstrated an equivalent IOP 
reduction through one year. Surprisingly, the AGI group required more glaucoma medications than the 
AIT group at 6 and 12 months.  
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Introduction 
Epibulbar glaucoma drainage devices are used to bypass the abnormal resistance to outflow in 
moderate to severe glaucoma ​[1]​. Similar to the Krupin glaucoma drainage implant ​[2]​, the first valved 
glaucoma device, the Ahmed glaucoma implant (AGI, New World Medical, Rancho Cucamonga, CA, USA) 
has a pressure-sensitive valve that is designed to open when the IOP is 8 mmHg to avoid complications 
related to hypotony during the early postoperative period ​[3]​. In contrast, the Trabectome (Neomedix 
Inc, Tustin, CA, USA), generates plasma to ablate the trabecular meshwork ​[4]​, which constitutes the 
primary resistance to outflow. This procedure is called ab interno trabeculectomy (AIT). Outflow 
resistance downstream of the trabecular meshwork and the episcleral venous pressure limit IOP 
reductions as compared to AGI while also preventing hypotony ​[5]​. Complications are relatively rare and 
similar to that seen in cataract surgery ​[6]​. AIT also lowers IOP rapidly but has been used only in mild to 
moderate glaucoma until it was recently described as an option for failed trabeculectomy ​[7]​ or failed 
epibulbar glaucoma drainage implants ​[8]​. AGI and AIT differ considerably in procedure times, cost 
[9,10]​, and complication profiles ​[6,11]​.  
Prior studies of AIT ​[12–17]​ and AGI ​[11,18]​ suggested a similar postoperative average IOP, but 
the patient populations might have different in glaucoma severity and type. Recent studies that 
stratified AIT outcomes by glaucoma severity indicated that patients with a higher preoperative IOP and 
more severe glaucoma experienced a larger IOP reduction ​[19–21]​. Because of this, we expanded our 
surgical indications to include those traditionally reserved for AIG and compared the outcomes in the 
present study. We hypothesized that AIG and AIT achieve a similar pressure reduction when similar 
glaucoma stages are compared.  
Although a randomized controlled trial remains the most effective tool to reduce bias and 
patient selection, modern statistical matching strategies ​[22–25]​ obtain a highly-balanced comparison of 
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already existing patient data. They also avoid non-routine practice patterns and a potential bias that 
may occur during patient recruitment in trials. We have used Coarsened Exact Matching before ​[26,27] 
to achieve a balanced comparison, but the challenge with potentially more uneven groups is that only a 
few patients in each group can be matched precisely.  The risk of achieving an overlap of matched 
features by those means is that regression toward the mean occurs which can make the comparison 
group look better or worse than they are. In contrast, the method we use here, ​Propensity Score 
Matching,​ uses a predicted probability of group membership to achieve a match ​[24,25,28]​.  
 
Methods 
This retrospective chart review was approved by the Institutional Review Board of the University 
of Pittsburgh (PRO14100026) and adhered to the tenets of the Declaration of Helsinki and the Health 
Insurance Portability and Accountability Act of 1996. Charts from October 2012 through February 2015 
were included that had a follow-up of at least one year. Inclusion criteria were at least 18 years of age 
undergoing Trabectome-mediated AIT or AGI surgery with at least 12 months of follow-up. All surgeries 
were performed by the same group of surgeons using the same surgical technique. Neovascular 
glaucoma was excluded.  
The main outcome measure was the postoperative IOP at one year. Secondary measures 
included the reduction of medications as well as success rates. Failure was defined (after the TVT)​[29]​ as 
anyone of postoperative IOP < 6, IOP > 21 mmHg, or <= 20% reduction in IOP from baseline at two 
consecutive visits after 3 months, or reoperation.  
All patients underwent a complete ophthalmologic examination before surgery and at each 
postoperative visit; this included best-corrected visual acuity, slit-lamp biomicroscopy, Goldmann 
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applanation tonometry and funduscopic evaluation. The indication for surgery (including the decision of 
which surgery to proceed with) was determined by the individual surgeon when the IOP was above the 
targeted IOP on maximally tolerated medical treatment. Procedures were performed by the same group 
of surgeons on comparable patient populations. The decisions to resume medications or to reoperate 
were also made by the individual surgeon. 
The glaucoma index (GI) is an indicator of the severity of glaucoma and its relative resistance to 
treatment ​[19–21]​. It is based on the visual field damage, the number of preoperative glaucoma 
medications, and the preoperative IOP. Visual field was separated into three categories: mild, moderate, 
or advanced visual field damage, which was assigned 1, 2, or 3 points, respectively. Preoperative number 
of medications were divided into four categories: 0–1, 2, 3 or 4+, and assigned a value of 1 to 4, 
respectively. Baseline IOP was divided into three categories: <20 mmHg, 20–29 mmHg, 30–39 mmHg, 
and greater than 40 mmHg and assigned from 1 to 4 points, respectively. GI was defined as the product 
of preoperative IOP × preoperative number of medications × VF and separated into four groups: <6 
(Group 1), 6–12 (Group 2), >12–18 (Group 3) and >18 (Group 4). 
Statistics 
Cases were matched with propensity-score matching (package “Matching” in R) ​[30,31]​ using a 
genetic algorithm based on age, gender, type of glaucoma, concurrent phacoemulsification, and baseline 
IOP and medications. Cases of AIT or AGI too different from their counterparts were excluded. Weighted 
linear regression was significant when p<0.05. A Kaplan-Meier survival curve for right-censored data 
with 80% confidence intervals was computed. A Cox proportional hazard model was developed to 
estimate the effects of 16, 21 and 26 mmHg preoperative IOP on surgical success. Data available beyond 
the 12 months was included in a secondary analysis and shown in average IOPs, medications, survival 
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and hazard graphs.  
Surgical Technique 
AIT was performed by creating a 1.8 mm uniplanar temporal clear corneal incision and ablating 
approximately 140 to 160 degrees of nasal TM under direct gonioscopic view. For AIT combined with 
phacoemulsification, the main incision was enlarged to 2.2 mm followed by a standard 
phacoemulsification. 
AGI tubes (model FP-7) were primed and sutured to the superotemporal sclera 10 mm posterior 
to the surgical limbus. The tube was trimmed so that it extended 1-2 mm onto the anterior surface of 
the iris and covered with a scleral patch graft.  
Patients in both groups used topical moxifloxacin and prednisolone acetate 1% four times per 
day. AIT patients also received pilocarpine 1% four times daily for one month then three times daily for 
one month. All preoperative glaucoma medications were stopped on the day of surgery and were added 
back later at the discretion of the surgeon. Postoperative clinic visits occurred at day 1, week 1, month 1, 
month 3, month 6 and month 12. 
 
Results 
Out of 102 AIT and 49 AGI patients, 66 were included in the study, consisting of 34 individuals in 
the AIT group and 32 in the AGI group ​(Fig 1)​. Using case matching, there was no significant difference in 
ethnicity, IOP, number of IOP-lowering medications, glaucoma type, the degree of VF loss and GI 
between AIT and AGI (p>0.05). ​Table 1​ shows baseline characteristics of each group.  
Fig 1. Ahmed glaucoma drainage device and Trabectome to scale.​ Devices are shown at the correct 
relative size and in the same eye for easier comparison. The Ahmed glaucoma drainage device has a 
valve to prevent overfiltration and a silicone plate with a surface area of 184 mm​2​ (left). The trabectome 
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is most commonly inserted through a temporal incision (nasal incision depicted in this illustration), and 
the trabecular meshwork is ablated along the nasal angle. The tip of the trabectome has a protective 
footplate that feeds the trabecular meshwork towards the active and passive electrode where plasma is 
generated (top right). The molecularized tissue is displaced by fluid from the irrigation ports and 
aspirated at the tip. 
 
Table 1. Baseline data of matched patients.  
 AIT AGI p 
n 34 32  
Age (years) 69.1  67.8  0.71 
Female (%) 61.8% 53.1% 0.48 
Ethnicity (%)   0.52 
    Asian 8.82% 3.12%  
    Black 26.5% 31.2%  
    White 64.7% 65.6%  
Baseline IOP (mmHg) 23.6±8.1 26.5+10.6 0.25 
Medications (n) 2.91  2.81  0.79 
With Phaco (%) 35.3% 31.2% 0.58 
Glaucoma Type (%)   0.46 
    POAG 52.9% 43.8%  
    Inflammatory 5.88% 12.5%  
    CACG 8.82% 12.5%  
    Steroid-induced 8.82% 9.38%  
    Other 23.5% 21.9%  
Degree of VF Loss       
    Average 2.4 (1-3) 2.5 (1-3) 0.5 
    Mild (1) 7 ( 20.6%) 5 (15.6%)  
    Moderate (2) 8 ( 23.5%) 5 (15.6%)  
    Severe (3) 19 (55.9%) 22 (68.8)  
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Glaucoma Index (GI)      
    Average 2.6 (1-4) 2.8 (1-4) 0.3 
    Group 1 9 (26.5%) 5 (15.6%)  
    Group 2 8 (23.5%) 10 (31.3%)  
    Group 3 6 (17.6%) 6 (18.8%)  
    Group 4 11 (23.4%) 11 (34.4%)  
IOP: intraocular pressure; POAG: primary open angle glaucoma; phaco: phacoemulsification; CACG: 
chronic angle closure glaucoma; VF: visual field. 
 
AIT group had a preoperative IOP of 23.6±8.1 mmHg compared to 26.5+10.6 mmHg  in AGI. The 
mean IOP at 1 week was 15.6±9.8 mmHg for AIT versus 15.7±7.2mmHg for AGI (p=0.9), 15.6±4.5 mmHg 
for AIT versus 16.4±6.4mmHg for AGI (p=0.4) at 3 months. At 6 months, the mean IOP was 13.4±6.2 
mmHg for AIT versus 16.3±5.2mmHg for AGI (p=0.06). At 12 months, the mean IOP was 14.5±8.7 mmHg 
for AIT versus 14.9±3.6mmHg for AGI (p=0.8). ​Fig 2​ illustrates the postoperative IOP changes.  
 
Fig 2. Intraocular pressure after Trabectome-mediated ab interno trabeculectomy (AIT) and Ahmed 
glaucoma implant (AGI).​ The intraocular pressure (IOP, average ± standard deviation) started diverging 
after three months but were not statistically different. Data for 24 months (AIT: n=24, AGI: n=20) and 30 
months ( AIT: n=18, AGI: n=12) are also shown but were not part of the match due to reduced numbers.  
 
The number of IOP-lowering medications ​(Fig 3)​ at three months was 2.7±1.4 for AIT versus 
3.6±1.7 (p=0.02). At six months, it was 2.6±1.8 for AIT versus 3.7±1.3 for AGI (p=0.018). At one year, the 
number of medications was 2.3±2.2 for AIT versus 3.6±1.3 for AGI (p=0.016).  
 
Fig 3. Glaucoma medications after Trabectome-mediated ab interno trabeculectomy (AIT) and Ahmed 
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glaucoma implant (AGI). ​The number of glaucoma medications (average ± standard deviation) started 
diverging after postoperative day 1 through 3 months but was not statistically different. Data for 24 
months (AIT: n=24, AGI: n=20) and 30 months (AIT: n=18, AGI: n=12) are also shown but were not part of 
the match due to reduced numbers.  
 
The survival analysis​ (Fig 4)​ indicated a similar survival for both AIT and AGI. While the survival 
declined faster for AIT at 300 days, the difference was not significant (as also evidenced by the 
confidence intervals that overlap the mean). Only six AIT patients (17.6%) required further surgery 
within the first 12 months 204+136 days compared to nine (28%) AGI patients who needed additional 
procedures after an average of 186+114 days from the time of their AGI surgery. The six AIT patients 
underwent two AGI surgeries and four transscleral diode cyclophotocoagulation (CPC) procedures to 
control IOP better. The nine additional procedures in the AGI group included three AGI revisions, four 
Baerveldt glaucoma shunt implantations, and two CPCs. Success was achieved in 76% of AIT and 69% of 
AGI (p=0.48).  
 
Fig 4. Survival analysis. Kaplan-Meier survival curve with 80% confidence intervals.​  AIT: 
Trabectome-mediated ab interno trabeculectomy. AGI: Ahmed glaucoma drainage implant. 
 
Cox proportional hazard modeling​ (Fig 5)​ was only possible for the preoperative IOP due to the 
limited number of eyes available for potential covariates. The Cox hazard model for different levels of 
preoperative IOP suggested that AIT did slightly better, lagging approximately 250 to 500 days behind 
AGI before survival had decreased similarly. However, due to the significant overlap of the confidence 
intervals, this was not statistically significant. Survival was best for higher preoperative IOPs with both 
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surgical modalities.  
 
Fig 5. Cox hazard model with different IOP criteria. ​The bands are the 80% confidence intervals. AGI: 
Ahmed glaucoma drainage implant. AIT: Trabectome-mediated ab interno trabeculectomy.  
 
Complications 
After AIT, the only complication was cystoid macular edema (CME) that occurred in a single case 
(0.8%) which was combined with phacoemulsification. After AGI, there were choroidal effusions in 7%, 
hypotony past three months in 2%, and diplopia in 2%. Visual acuity decreased by ≥ 2 Snellen lines after 
one year in 0% of AIT and 3% of AGI. 
 
Discussion 
In this study, we found that Trabectome-mediated ab interno trabeculectomy (AIT) and Ahmed 
glaucoma drainage devices (AGI) achieved a similar IOP reduction but have a complication profile that 
favors AIT. Although AIT is a mature microincisional glaucoma surgery that was introduced almost 15 
years ago, no study has compared trabecular bypass or ablation to traditional glaucoma surgeries. We 
used propensity score matching to compare AIT, which enhances outflow along the physiological, 
conventional outflow route and Ahmed glaucoma implants, a valved epibulbar drainage device, which 
allows bypassing both the conventional and the uveoscleral outflow. Because these surgeries involve 
such fundamentally different mechanisms and surgical effort, AGIs are typically used in advanced 
glaucomas with a high IOP while AIT is commonly performed in mild glaucomas with straightforward 
access to the trabecular meshwork.  We expanded our practice pattern to use AIT as a first surgery for 
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even uncontrolled glaucomas often reserved for AGI because our studies suggested that AIT can be used 
after failed trabeculectomy ​[7]​, in narrow angles ​[32]​ and more severe glaucoma ​[19–21] 
The AGI group required a reintervention rate that was 1.6 times more frequent than AIT while 
also requiring more medications. In contrast, patients who underwent AIT had no serious complications. 
AIT offered a safer alternative to a mean final IOP of 14.5±8.7 mmHg, a 30% decrease from baseline. The 
final IOP achieved here in AIT and reduction of medications is quite similar to the mean of the largest AIT 
series (n=4,659), in which the mean IOP fell from 23.1 to 16.2 after 12 months (30% decrease) on 0.7 
fewer medications ​[33]​. Analysis of both the degree of VF loss as well as the GI revealed no statistical 
difference in glaucoma severity between the two groups. The additional data presented here beyond 
the focus of 1-year outcomes suggests that both procedures remain comparable for approximately 2.5 
years. 
Survival analysis is helpful to detail how much IOP data is being censored, for instance when IOP 
data is no longer included in the mean IOP because of a second surgery. In one study on AIT (n=246), the 
mean final IOP after four years was 12 mmHg (45% decrease from baseline) on 0.5 fewer medications, 
yet paradoxically, the authors recommended that trabectome should only be used when the goal IOP is 
> 21 mmHg ​[15,34]​. The main reason was the guarded success rates because only 64% of cases met TVT 
success criteria ​[29]​ after one year and only 28% were successful using an IOP cutoff of 18 mmHg. In 
contrast, our study showed no statistically significant difference between the success rates for both 
groups. Compared to our success rate, the ABC trial reported a higher success rate of 84% for AGI at one 
year. As a broader measure of failure, the reoperation rate was 1.6 times greater in AIG than in AIT. 
Likely the main reason why AIT has never been reported to be more successful than penetrating surgery 
is that both trabeculectomy and aqueous shunts bypass not only the site of highest resistance to 
aqueous outflow in the TM, but also the proximal collector channel pathway that limits IOP to 
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approximately twice of that of the episcleral venous pressure. This indicates that a yet to be identified 
outflow resistance must exist. We applied a Cox hazard model to estimate the effects of covariates. At 
least 10 to 15 observations are needed for each parameter fit in a regression model to prevent 
overfitting ​[35]​. Given the approximately 60 eyes that were in this dataset after matching, this directed 
us to attempt to fit no more than four to six covariates, but because of the number of failures in the 
survival analysis, only two to three covariates could be attempted to fit. We assumed a priori that 
baseline IOP would have an effect on the outcome of surgery because at a minimum the IOP threshold 
for failure depended on the preoperative IOP. Therefore, a Cox proportional hazards model should at 
least model a linear relationship between baseline IOP and subsequent surgical failure while additional 
degrees of freedom would be desirable. Our prior studies indicated that the effect of prior cataract 
surgery is extremely limited or absent ​[26,27]​ even in narrow angles ​[32]​. Because of the limited number 
of eyes in this analysis, we only modeled IOP. 
It is surprising that AGIs that bypass the conventional outflow tract are not more successful than 
AIT that relies on patency of a functioning outflow system that is downstream of the ablated trabecular 
meshwork. Recent discoveries of segmental ​[36,37]​, circumferential flow ​[38–40]​, and fascinating 
discoveries of valve like elements in collector channels ​[4,41]​ highlight the complexity of the 
conventional outflow route. The advantage of tube shunts to bypass those is likely negated by the 
fibrosis and chronic foreign body reaction to a silicone drainage implant that is patient specific and cause 
a variable diffusion barrier ​[42]​.  
Because a conjunctival bleb and an implant are avoided entirely in AIT, it is considerably safer 
than either trabeculectomy ​[43]​ or aqueous shunts. Complications in the ABC required intervention in 
42% of Baerveldt glaucoma drainage devices and 26% of AGIs ​[44]​. The rate of endophthalmitis in a large 
series of 542 aqueous shunts was 1.7% ​[45]​. Endophthalmitis has only been reported once after AIT ​[46] 
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and may approach the rate of phacoemulsification (i.e. 0.04% of 1 million cases) ​[47]​. In our study, AIT 
only had a single complication of CME in one case (0.9%) compared to choroidal effusions in 7% of AGI 
with 41% requiring further interventions in the form of cyclodestruction or additional tube shunts. The 
rate of vision loss is also high: after one year, two or more Snellen lines of visual acuity were lost in 
30-34% for both AGIs and Baerveldt implants in the ABC, AVB, and TVT studies. Most of the AIT 
literature directly specifies that no patient in the study lost two lines of vision. There is a single study 
that noted that 13 patients (5%) lost >2 lines of vision, but there is no clarification given specifying the 
reason for vision loss or whether those patients had received combined phaco-AIT versus standalone AIT 
[15]​. Persistent hypotony is exceedingly rare ​[6]​. The only patients in our study who lost >2 Snellen lines 
of visual acuity were all in the AGI group (3%). 
Limitations of this study were the modest number of AGI-only patients of a single surgeon (NAL) 
that resulted in a limited recruitment window for the match. We have since started to combine both AIT 
and AGI to achieve an even lower IOP on fewer medications in more advanced glaucoma.  
Conclusions 
Using propensity score matching, AIT resulted in an IOP reduction, final IOP and success rate at 
one year that is similar to AGI in groups of equivalent glaucoma severity. Patients who underwent AIT 
required fewer interventions, fewer medications and had a more favorable complication profile. All of 
these advantages combined with the fact that the conjunctiva is not violated and that no hardware is 
implanted make AIT an appropriate first surgical option for patients with medically uncontrolled 
glaucoma. Results of this study will allow for the design of future comparative studies as well as to justify 
crossover in the case of failure.  
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Figures and Tables 
Figure 1 
 
Fig 1. Ahmed glaucoma drainage device and Trabectome to scale. ​Devices are shown at the correct 
relative size and in the same eye for easier comparison. The Ahmed glaucoma drainage device has a 
valve to prevent overfiltration and a silicone plate with a surface area of 184 mm​2​ (left). The trabectome 
is most commonly inserted through a temporal incision (nasal incision depicted in this illustration), and 
the trabecular meshwork is ablated along the nasal angle. The tip of the trabectome has a protective 
footplate that feeds the trabecular meshwork towards the active and passive electrode where plasma is 
generated (top right). The molecularized tissue is displaced by fluid from the irrigation ports and 






Fig 2. Intraocular pressure after Trabectome-mediated ab interno trabeculectomy (AIT) and Ahmed 
glaucoma implant (AGI).​ The intraocular pressure (IOP, average ± standard deviation) started diverging 
after three months but were not statistically different. Data for 24 months (AIT: n=24, AGI: n=20) and 30 
months ( AIT: n=18, AGI: n=12) are also shown but were not part of the match due to reduced numbers.  
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 Figure 3 
 
Fig 3. Glaucoma medications after Trabectome-mediated ab interno trabeculectomy (AIT) and Ahmed 
glaucoma implant (AGI). ​The number of glaucoma medications (average ± standard deviation) started 
diverging after postoperative day 1 through 3 months but was not statistically different. Data for 24 
months (AIT: n=24, AGI: n=20) and 30 months (AIT: n=18, AGI: n=12) are also shown but were not part of 
the match due to reduced numbers.  
 
20 
 Fig 4. Survival analysis. Kaplan-Meier survival curve with 80% confidence intervals. ​ AIT: 
Trabectome-mediated ab interno trabeculectomy. AGI: Ahmed glaucoma drainage implant. 
 
 
Fig 5. Cox hazard model. Kaplan-Meier survival curve (top left) and Cox proportional hazard models 
(right) with three different IOP criteria. ​The bands are the 80% confidence intervals. AGI: Ahmed 
21 
glaucoma drainage implant. AIT: Trabectome-mediated ab interno trabeculectomy.  
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